Last reviewed · How we verify
protamine
At a glance
| Generic name | protamine |
|---|---|
| Also known as | promin |
| Sponsor | Mustafa Kemal University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Heparin overdose
Common side effects
- Hypoglycemia
- Headache
- Influenza-like symptoms
- Upper respiratory tract infection
- Dyspepsia
- Headache
- Diarrhea
- Neuropathy
- Back pain
- Diarrhea
- Pharyngitis
- Pharyngitis
Serious adverse events
- Severe Hypoglycemia
- Severe Hypoglycemia
- Anaphylaxis
- Worsening of diabetic retinopathy
- Acute painful peripheral neuropathy
- Ophthalmologic refraction disorder
- Erythema
- Edema
- Allergic reactions
Key clinical trials
- Dose for Reversal of Heparin After Cardiopulmonary Bypass (NA)
- SIRAKI 02 Posthoc Analysis. (NA)
- Routine Versus Selective Protamine Administration to Reduce Bleeding Complications After Transcatheter Aortic Valve Implantation (POPular ACE TAVI) (PHASE4)
- DDAVP Effect by TEG6 in Cardiac Surgery
- Antagonization of Heparin With Protamine Sulfate After TAVI (PHASE3)
- Assessment of Artificial Intelligence Algorithms for ROTEM
- Coagulation in Acute Aortic Dissection (NA)
- Use of PRP in Open Surgery for Type A Aortic Dissection (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- protamine CI brief — competitive landscape report
- protamine updates RSS · CI watch RSS
- Mustafa Kemal University portfolio CI